Late non-fasting plasma glucose predicts cardiovascular mortality independent of hemoglobin A1c

被引:0
作者
Yutang Wang
Yan Fang
机构
[1] Federation University Australia,Discipline of Life Sciences, School of Science, Psychology and Sport
来源
Scientific Reports | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
It is unknown whether non-fasting plasma glucose (PG) is associated with cardiovascular disease (CVD) mortality. This study aimed to investigate this association in US adults. This study included adults from the National Health and Nutrition Examination Surveys from 1988 to 2014. Mortality outcomes were ascertained by linkage to the National Death Index records. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of PG for CVD mortality. Among 34,907 participants, 1956, 5564, and 27,387 had PG from participants in early non-fasting, late non-fasting, and fasting states, respectively (defined as a period since last calorie intake of 0–2.9, 3.0–7.9, or ≥ 8.0 h, respectively). This cohort was followed up for 455,177 person-years (mean follow-up, 13.0 years), with 2,387 CVD deaths being recorded. After adjustment for all confounders including hemoglobin A1c (HbA1c), only late non-fasting PG (continuous, natural log-transformed) was positively associated with CVD mortality risks (hazard ratio, 1.73; 95% confidence interval 1.12–2.67). Higher late non-fasting PG (dichotomous, at a cut-off of 105, 110, or 115 mg/dL) was associated with higher CVD mortality risks. In addition, at the cut-off of 115 mg/dL, higher late non-fasting PG was associated with higher CVD mortality risks in those with either a normal (< 5.7%) or prediabetic HbA1c level (from 5.7 to 6.4%). In conclusion, late non-fasting PG predicts CVD mortality independent of HbA1c. Late non-fasting PG with a cut-off of 115 mg/dL may be used to identify those at high CVD risk.
引用
收藏
相关论文
共 69 条
[1]  
Meigs JB(2002)Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study Diabetes Care 25 1845-1850
[2]  
Nathan DM(2006)Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study Diabetes Care 29 26-31
[3]  
D’Agostino RB(2007)Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Circulation 116 151-157
[4]  
Wilson PWF(2019)2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J. Am. Coll. Cardiol. 74 e177-e232
[5]  
Brunner EJ(2021)2. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2021 Diabetes Care 44 S15-S33
[6]  
Shipley MJ(2011)The pros and cons of diagnosing diabetes with A1C Diabetes Care 34 S184-S190
[7]  
Witte DR(2009)Postprandial glucose—A potential therapeutic target to reduce cardiovascular mortality Curr. Vasc. Pharmacol. 7 68-74
[8]  
Fuller JH(2009)Target for glycemic control: Concentrating on glucose Diabetes Care 32 S199-204
[9]  
Marmot MG(1996)Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up Diabetologia 39 1577-1583
[10]  
Barr EL(2017)Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes J. Diabetes Investig. 8 600-608